Anixa Biosciences Inc Stock Price, News & Analysis

Anixa Biosciences (NASDAQ: ANIX) has been awarded U.S. Patent Number 12,370,244, extending protection for its breast cancer vaccine technology into the mid-2040s. The patent covers novel immunization methods using human α-lactalbumin protein, which is expressed during lactation and in certain breast cancers.

Developed in collaboration with Cleveland Clinic, this vaccine represents a pioneering approach to breast cancer prevention, targeting a significant unmet need. With 297,000 new cases of invasive breast cancer projected in 2025 and 43,000 expected deaths in the U.S., the technology addresses a potential multi-billion dollar market opportunity, particularly for women at risk of triple-negative breast cancer (TNBC).

Anixa Biosciences (NASDAQ: ANIX) announced the upcoming issuance of U.S. Patent Number 12,357,593 on July 15, 2025, strengthening its intellectual property portfolio for ovarian cancer vaccine technology. The patent covers methods of eliciting immune responses targeting anti-Müllerian hormone receptor, type II (AMHR2), a key target for ovarian cancer prevention and treatment.

The vaccine technology, developed in collaboration with Cleveland Clinic and the National Cancer Institute, focuses on preventing and treating ovarian cancer, particularly in high-risk populations with BRCA mutations or family history. The patent, issued to Cleveland Clinic with Anixa holding worldwide rights, includes methods for administering immunogenic compositions comprising nucleic acid encoding AMHR2 polypeptide.

Anixa Biosciences (NASDAQ: ANIX) has initiated dosing in the fourth cohort of its Phase 1 clinical trial for ovarian cancer CAR-T therapy. The new cohort will receive 3 million CAR-positive cells per kg of body weight, a 30-fold increase from the first cohort. The trial, conducted at Moffitt Cancer Center, showed no dose-limiting toxicities in the third cohort. The study evaluates a novel CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR), which is specifically expressed on ovarian cells and tumor vasculature. The trial enrolls adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, focusing on safety, maximum tolerated dose, and efficacy monitoring. CEO Amit Kumar noted promising early efficacy signs despite the trial's primary focus on safety.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced an upcoming investor webcast scheduled for June 26, 2025, at 2:00 PM EDT. During the presentation, CEO Dr. Amit Kumar will provide a comprehensive overview of the company's business strategy, therapeutic portfolio, market opportunities, and upcoming milestones. The interactive webcast will include a Q&A session for investors. Pre-registration is required through a provided Zoom link, and a recording of the webcast along with the presentation materials will be made available on Anixa's investor relations website.

Anixa Biosciences (NASDAQ: ANIX) announced national media coverage of its breast cancer vaccine on Fox News' 'Fox & Friends' and in the New York Post. The company's innovative vaccine aims to prevent breast cancer by targeting α-lactalbumin, a protein normally expressed only during lactation but also found in breast cancer cells. The vaccine is designed to train the immune system to identify and destroy cancerous cells before they develop into invasive tumors by activating cytotoxic T cells against cells expressing α-lactalbumin. This preventive approach could potentially revolutionize breast cancer treatment by providing preemptive immune protection against emerging breast tumors.

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham from Moffitt Cancer Center will present an e-poster at the ESMO Gynaecological Cancers Congress 2025 in Vienna, Austria. The presentation will focus on their Phase 1 clinical trial investigating an ovarian cancer CAR-T immunotherapy. Dr. Wenham, who chairs the Gynecologic Oncology Program at Moffitt Cancer Center, is the principal investigator of the trial. The therapy involves autologous T-cells that are genetically engineered with a chimeric receptor targeting the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation is scheduled for June 19-21, 2025.

Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar was featured on NewsNation's 'Elizabeth Vargas Reports' discussing their innovative breast cancer vaccine. The vaccine targets α-lactalbumin, a protein normally expressed during lactation but also present in breast cancer cells. By training the immune system to recognize and eliminate cells expressing this protein, the vaccine aims to prevent tumor development. The company has completed enrollment in its Phase 1 clinical trial, marking a significant milestone in the vaccine's development. The interview highlighted the potential revolutionary impact of this preventative cancer immunotherapy approach in breast cancer treatment and prevention.

Anixa Biosciences has completed enrollment in its Phase 1 breast cancer vaccine trial, developed in partnership with Cleveland Clinic and funded by the Department of Defense. The trial enrolled 35 participants across three cohorts: 26 triple-negative breast cancer survivors at risk of recurrence, 4 high-risk individuals undergoing preventative mastectomy, and 5 patients receiving pembrolizumab treatment. Preliminary results show over 70% of patients demonstrating protocol-defined immune responses, with the vaccine being well-tolerated. The final patient visits are scheduled for August 2025, after which results will be submitted to the DoD and FDA. The vaccine targets a novel pathway in immuno-oncology and aims to address unmet needs in breast cancer prevention and treatment, particularly for TNBC and genetically high-risk populations.

Anixa Biosciences (NASDAQ: ANIX) CEO provided a shareholder update highlighting significant progress in their cancer treatment programs. The company maintains strong financial health with $17 million in cash, no debt, and a low annual burn rate of $7 million. Their CAR-T therapy program for ovarian cancer has completed three dose-escalation cohorts, with encouraging survival data in early trials. The breast cancer vaccine program, developed with Cleveland Clinic, is nearing Phase 1 completion with over 70% of patients showing immune responses. The vaccine targets three groups: triple-negative breast cancer survivors, high-risk individuals, and patients with residual disease. Key upcoming milestones include final Phase 1 data presentation at the San Antonio Breast Cancer Symposium in December 2025, FDA interactions for Phase 2, and initiation of Cohort 4 for the CAR-T program.